Use of catheter ablation to delay the progression of atrial fibrillation

Paroxysmal AF can progress to persistent AF, increasing the risk of myocardial infarction, thromboembolism, and stroke. Delaying this development is imperative, but data on the long-term clinical impact of treatments that postpone progression is limited. The ATTEST trial aimed to determine whether irrigated catheter ablation treatment together with a three-dimensional electroanatomic mapping system can delay the progression of AF when compared to therapy with an antiarrhythmic drug, or AAD, over the course of 3 years. This content is intended for Health Care Professionals in Southeast Asia.